ArticleJournal of molecular medicine (Berlin, Germany)2026
Targeting EFEMP1 enhances chondrogenesis and inhibits hypertrophic differentiation in a spontaneous osteoarthritis mouse model.
Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage degradation. EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) has been implicated in cartilage development and OA pathogenesis, as its expression inhibits chondrogenesis and declines during mesenchymal stem cell differentiation. This study was aimed at investigating the role of EFEMP1 in cartilage regulation and evaluating the therapeutic potential of EFEMP1 inhibition in OA. EFEMP1 knockdown mediated by small interfering RNA (siRNA) was performed in human chondrocyte and mouse preosteoblast cultures. In chondrocytes, EFEMP1 knockdown downregulated hypertrophic markers (MMP-13, COL10A1) and upregulated SOX9 and aggrecan. Furthermore, phosphokinase analysis revealed increased activities of p70S6K, β-catenin, and HSP60. In osteoblasts, EFEMP1 knockdown reduced RUNX2 expression, calcification, and ALP activity. In vivo, STR/ort spontaneous OA mice were treated with EFEMP1-neutralizing antibody to assess cartilage preservation and cytokine modulation. As a result, EFEMP1 antibody treatment increased matrix-producing chondrocytes, improved cartilage integrity, and lowered OARSI scores. It also enhanced SOX9 and COL2A1 expression while suppressing COL10A1. Although no significant changes were observed in subchondral bone parameters, cytokine analysis revealed a chondroprotective effect in the EFEMP1 antibody-treated group. In conclusion, EFEMP1 inhibition promotes chondrogenesis, suppresses chondrocyte hypertrophy, and modulates inflammatory signaling, contributing to cartilage preservation and attenuation of OA progression. These findings identify EFEMP1 as a potential therapeutic target for OA. KEY MESSAGES: EFEMP1 inhibition promotes chondrogenesis and reduces hypertrophic markers, supporting cartilage maintenance and delaying OA progression. EFEMP1 antibody treatment enhances chondroprotective cytokines while suppressing inflammatory cytokines, contributing to joint preservation in OA mice. Despite its beneficial effects on cartilage, EFEMP1 inhibition does not significantly alter subchondral bone parameters, highlighting its selective role in OA pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.